

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB** 1/9/1987  
**Gender:** Female  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Antimicrobial Susceptibility, AFB/Mycobacteria**

ARUP test code 0060217

Collected: 00/00/0000 00:00 MT  
Started: 00/00/0000 00:00 MT

Source: **Respiratory**

Body Site: **Sputum**

Free Text Sources:

**Final Report**

Mycobacteroides (Mycobacterium) chelonae  
Organism identified by client

**Susceptibility Results**

**Organism: Mycobacteroides (Mycobacterium) chelonae**

<b>Cefoxitin</b>	Interpretation: <b>RESISTANT</b> MIC (ug/mL): <b>&gt;=256</b>
<b>Ciprofloxacin</b>	Interpretation: <b>RESISTANT</b> MIC (ug/mL): <b>8</b>
<b>Clarithromycin</b>	Interpretation: <b>SUSCEPTIBLE</b> MIC (ug/mL): <b>0.25</b>
<b>Doxycycline</b>	Interpretation: <b>RESISTANT</b> MIC (ug/mL): <b>16</b>

**S=Susceptible, I=Intermediate, R=Resistant, NonS=Nonsusceptible, IND=Indeterminate, SDD=Susceptibility is dose dependent, None=Interpretive guidelines are not available**

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 20-281-102891  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 1 of 2 | Printed: 10/12/2020 10:42:38 AM  
4848

<b>Imipenem</b>	Interpretation: <b>INTERMEDIATE</b> MIC (ug/mL): <b>8</b>
<b>Linezolid</b>	Interpretation: <b>INTERMEDIATE</b> MIC (ug/mL): <b>16</b>
<b>Minocycline</b>	MIC (ug/mL): <b>16</b>
<b>Moxifloxacin</b>	Interpretation: <b>RESISTANT</b> MIC (ug/mL): <b>8</b>
<b>Tigecycline</b>	MIC (ug/mL): <b>0.12</b>
<b>Tobramycin</b>	Interpretation: <b>SUSCEPTIBLE</b> MIC (ug/mL): <b>2</b>
<b>Trimethoprim/Sulfamethoxazole</b>	Interpretation: <b>RESISTANT</b> MIC (ug/mL): <b>8/152</b>

**Interpretive Information** Interpretation: **SEE NOTE**  
Significant infections caused by rapidly growing mycobacteria should not be treated with clarithromycin alone. Updated CLSI guidelines (M24, 3rd ed. 2018). For phenotypic detection of inducible resistance, the final clarithromycin reading should be at 14 days. Species and subspecies that are known to have a non-functional or absent "erm" gene and therefore are expected to be susceptible to clarithromycin are: *M. abscessus* subsp. *massiliense*, *M. chelonae*, *M. immunogenum*, *M. mucogenicum* group, *M. peregrinum*, and *M. senegalense*.

**Interpretive Results**  
Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
Antimicrobial Susceptibility, AFB/Mycobacteria	20-281-102891	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

**S=Susceptible, I=Intermediate, R=Resistant, NonS=Nonsusceptible, IND=Indeterminate, SDD=Susceptibility is dose dependent, None=Interpretive guidelines are not available**

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at: